Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer

BACKGROUND: Despite neoadjuvant/adjuvant chemotherapy, women with resectable stage II/III breast cancer (BC) have high risk of recurrent disease. Recent data suggest that zoledronic acid (ZOL) therapy concurrent with adjuvant treatments may improve cancer-related outcomes in patients with BC. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Aft, R L, Naughton, M, Trinkaus, K, Weilbaecher, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389411/
https://www.ncbi.nlm.nih.gov/pubmed/22617128
http://dx.doi.org/10.1038/bjc.2012.210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389411/
https://www.ncbi.nlm.nih.gov/pubmed/22617128
http://dx.doi.org/10.1038/bjc.2012.210

Ejemplares similares